Multicenter randomized phase III study comparing docetaxel with carboplatin versus docetaxel single agent as second line treatment in patients with non-small cell lung cancer (NSCLC).

Trial Profile

Multicenter randomized phase III study comparing docetaxel with carboplatin versus docetaxel single agent as second line treatment in patients with non-small cell lung cancer (NSCLC).

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2010

At a glance

  • Drugs Docetaxel (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2009 Actual patient numbers (135) added as reported by ClinicalTrials.gov.
    • 20 Jul 2008 Status changed recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Jul 2008 Actual end date is now 1 May 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top